Shilpa Medicare profit hits ₹108 cr as pharma operations turn around
Consolidated net profit grew sevenfold in the March quarter while the company moved to buy a 28% stake in Neo Green Power.
— 1 earlier story on Shilpa Medicare Ltd. →What's new with Shilpa Medicare Ltd.
- Q4 consolidated revenue rose 32% to ₹437 cr.
- Standalone profit swung to ₹71 cr from a ₹5.6 cr loss last year.
- The board approved a 28% stake in Neo Green Power for ₹4.44 cr.
Why this matters for Shilpa Medicare Ltd.
The jump from a standalone loss to a ₹71 cr profit marks a shift from prior-year volatility. While associate contributions helped, the core business turnaround suggests that internal consolidation is now affecting cash flow.
What we're watching
- Sustainability of service income without one-time gains.
- Integration results from the merged wholly-owned subsidiaries.
- Impact of shifting the registered office from Karnataka to Maharashtra.
The full read
Shilpa Medicare finished FY26 with a change in performance. Consolidated revenue rose 32% to ₹437 crore for the March quarter. Net profit reached ₹108 crore against ₹14.5 crore a year ago, aided by an ₹18.2 crore share of profit from a foreign associate and gains from a joint venture stake sale. The standalone results confirm the shift, moving from a ₹5.6 crore loss in Q4FY25 to a ₹71 crore profit. The company is using its cash position to pay a 60 paise dividend and put ₹4.44 crore into a 28% stake in Neo Green Power. Moving the registered office from Karnataka to Maharashtra marks a change for the board. The next test is whether the pharma business maintains this profit growth without non-operating income.